307 related articles for article (PubMed ID: 28859621)
1. NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity.
Li Q; Liu X; Jin K; Lu M; Zhang C; Du X; Xing B
BMC Cancer; 2017 Aug; 17(1):605. PubMed ID: 28859621
[TBL] [Abstract][Full Text] [Related]
2. NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2.
Liu X; Tan Y; Zhang C; Zhang Y; Zhang L; Ren P; Deng H; Luo J; Ke Y; Du X
EMBO Rep; 2016 Mar; 17(3):349-66. PubMed ID: 26882543
[TBL] [Abstract][Full Text] [Related]
3. High expression of N-acetyltransferase 10: a novel independent prognostic marker of worse outcome in patients with hepatocellular carcinoma.
Zhang X; Liu J; Yan S; Huang K; Bai Y; Zheng S
Int J Clin Exp Pathol; 2015; 8(11):14765-71. PubMed ID: 26823802
[TBL] [Abstract][Full Text] [Related]
4. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
Zhang MF; Zhang ZY; Fu J; Yang YF; Yun JP
J Transl Med; 2009 Dec; 7():110. PubMed ID: 20025780
[TBL] [Abstract][Full Text] [Related]
5. Loss of nucleolar localization of NAT10 promotes cell migration and invasion in hepatocellular carcinoma.
Tan Y; Zheng J; Liu X; Lu M; Zhang C; Xing B; Du X
Biochem Biophys Res Commun; 2018 May; 499(4):1032-1038. PubMed ID: 29634924
[TBL] [Abstract][Full Text] [Related]
6. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
8. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
9. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
10. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
11. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression.
Deng M; Zhang L; Zheng W; Chen J; Du N; Li M; Chen W; Huang Y; Zeng N; Song Y; Chen Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):9. PubMed ID: 36609449
[TBL] [Abstract][Full Text] [Related]
13. Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.
He X; Liu F; Yan J; Zhang Y; Yan J; Shang H; Dou Q; Zhao Q; Song Y
Sci Rep; 2015 Mar; 5():8705. PubMed ID: 25732051
[TBL] [Abstract][Full Text] [Related]
14. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma.
Qiu SJ; Ye SL; Wu ZQ; Tang ZY; Liu YK
J Cancer Res Clin Oncol; 1998; 124(5):253-8. PubMed ID: 9645455
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
16. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
[TBL] [Abstract][Full Text] [Related]
17. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.
Wang W; Cheng JW; Qin JJ; Hu B; Li X; Nijampatnam B; Velu SE; Fan J; Yang XR; Zhang R
Cancer Lett; 2019 Sep; 459():156-167. PubMed ID: 31181320
[TBL] [Abstract][Full Text] [Related]
18. Upregulated TRIM11 Exerts its Oncogenic Effects in Hepatocellular Carcinoma Through Inhibition of P53.
Liu J; Rao J; Lou X; Zhai J; Ni Z; Wang X
Cell Physiol Biochem; 2017; 44(1):255-266. PubMed ID: 29190611
[TBL] [Abstract][Full Text] [Related]
19. Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma.
Koom WS; Park SY; Kim W; Kim M; Kim JS; Kim H; Choi IK; Yun CO; Seong J
J Radiat Res; 2012; 53(2):202-10. PubMed ID: 22510592
[TBL] [Abstract][Full Text] [Related]
20. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
